Compare Stocks: CODX, KYNB, ALGS, and BCTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.17 +2.4%	$5.85	$3.98 ▼ $13.69	$32.26M	2.34	149,258 shs	21,703 shs
BCTX Briacell Therap	$4.22 +18.5%	$3.62	$2.60 ▼ $14.68	$36.71M	1.1	337,377 shs	497,922 shs
CODX Co-Diagnostics	$0.94 -0.1%	$1.58	$0.93 ▼ $46.50	$6.56M	2.85	2.52 million shs	270,321 shs
KYNB Kyntra Bio	$7.10 -6.7%	$7.46	$6.32 ▼ $12.58	$28.76M	1.06	22,719 shs	38,618 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	+1.20%	-8.18%	-23.14%	-4.36%	-43.58%
BCTX Briacell Therap	-0.56%	-1.93%	+5.01%	+22.76%	-56.64%
CODX Co-Diagnostics	-17.47%	-16.00%	-29.79%	-72.08%	-95.09%
KYNB Kyntra Bio	-2.06%	-5.35%	+11.75%	+13.58%	+760,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.17 +2.4%	$5.85	$3.98 ▼ $13.69	$32.26M	2.34	149,258 shs	21,703 shs
BCTX Briacell Therap	$4.22 +18.5%	$3.62	$2.60 ▼ $14.68	$36.71M	1.1	337,377 shs	497,922 shs
CODX Co-Diagnostics	$0.94 -0.1%	$1.58	$0.93 ▼ $46.50	$6.56M	2.85	2.52 million shs	270,321 shs
KYNB Kyntra Bio	$7.10 -6.7%	$7.46	$6.32 ▼ $12.58	$28.76M	1.06	22,719 shs	38,618 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	+1.20%	-8.18%	-23.14%	-4.36%	-43.58%
BCTX Briacell Therap	-0.56%	-1.93%	+5.01%	+22.76%	-56.64%
CODX Co-Diagnostics	-17.47%	-16.00%	-29.79%	-72.08%	-95.09%
KYNB Kyntra Bio	-2.06%	-5.35%	+11.75%	+13.58%	+760,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	644.68% Upside
BCTX Briacell Therap	1.00	Sell	N/A	N/A
CODX Co-Diagnostics	2.50	Moderate Buy	$67.50	7,078.56% Upside
KYNB Kyntra Bio	2.50	Moderate Buy	$37.25	424.65% Upside

Current Analyst Ratings Breakdown

Latest CODX, KYNB, ALGS, and BCTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$41.00
9/16/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	CODX Co-Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/1/2026	KYNB Kyntra Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/18/2026	CODX Co-Diagnostics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/14/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	BCTX Briacell Therap	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	14.73	N/A	N/A	$8.67 per share	0.60
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$9.20 per share	N/A
CODX Co-Diagnostics	$620K	10.59	N/A	N/A	$9.14 per share	0.10
KYNB Kyntra Bio	$6.44M	4.47	N/A	N/A	($4.20) per share	-1.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
BCTX Briacell Therap	-$26.31M	-$7.92	N/A	N/A	N/A	N/A	-153.53%	-129.26%	N/A
CODX Co-Diagnostics	-$46.90M	-$10.32	N/A	N/A	N/A	-6,531.77%	-210.99%	-174.97%	11/5/2026 (Estimated)
KYNB Kyntra Bio	$183.45M	$45.30	0.16	N/A	N/A	2,199.13%	N/A	-47.27%	N/A

Latest CODX, KYNB, ALGS, and BCTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	CODX Co-Diagnostics	-$3.00	-$1.46	+$1.54	-$1.46	$0.13 million	$0.17 million
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
CODX Co-Diagnostics	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
BCTX Briacell Therap	N/A	7.07	7.07
CODX Co-Diagnostics	N/A	1.81	1.52
KYNB Kyntra Bio	N/A	2.69	2.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
BCTX Briacell Therap	15.42%
CODX Co-Diagnostics	14.99%
KYNB Kyntra Bio	72.71%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
BCTX Briacell Therap	0.74%
CODX Co-Diagnostics	2.30%
KYNB Kyntra Bio	4.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	82	6.24 million	5.76 million	No Data
BCTX Briacell Therap	4	8.70 million	8.64 million	No Data
CODX Co-Diagnostics	100	6.98 million	6.82 million	No Data
KYNB Kyntra Bio	570	4.05 million	3.88 million	N/A

CODX, KYNB, ALGS, and BCTX Headlines

Recent News About These Companies

Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 2, 2026 | globenewswire.com

Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation

August 31, 2026 | globenewswire.com

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2026 | zacks.com

Kyntra Bio: Q2 Earnings Snapshot

August 13, 2026 | chron.com

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Kyntra Bio to Report Second Quarter 2026 Financial Results

August 7, 2026 | markets.businessinsider.com

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?

August 3, 2026 | zacks.com

Kyntra Bio Inc KYNB

August 1, 2026 | morningstar.comM

Kyntra Bio Inc (KYNB)

June 24, 2026 | zacks.com

Kyntra Bio (KYNB) Stock Forecast & Price Target

June 13, 2026 | investing.com

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk ...

June 11, 2026 | finance.yahoo.com

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

June 11, 2026 | globenewswire.com

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

May 11, 2026 | seekingalpha.com

Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

May 11, 2026 | zacks.com

Kyntra Bio to Report First Quarter 2026 Financial Results

May 4, 2026 | globenewswire.com

Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know

April 14, 2026 | zacks.com

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026 | globenewswire.com

Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript

March 16, 2026 | seekingalpha.com

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 16, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX, KYNB, ALGS, and BCTX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$5.17 +0.12 (+2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$5.18 +0.00 (+0.10%)

As of 04:15 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Briacell Therap NASDAQ:BCTX

$4.22 +0.66 (+18.54%)

Closing price 04:00 PM Eastern

Extended Trading

$4.28 +0.06 (+1.45%)

As of 06:58 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Co-Diagnostics NASDAQ:CODX

$0.94 0.00 (-0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$0.95 +0.01 (+1.03%)

As of 06:48 PM Eastern

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Kyntra Bio NASDAQ:KYNB

$7.10 -0.51 (-6.70%)

Closing price 04:00 PM Eastern

Extended Trading

$7.26 +0.16 (+2.25%)

As of 04:10 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CODX, KYNB, ALGS, and BCTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CODX, KYNB, ALGS, and BCTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CODX, KYNB, ALGS, and BCTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX, KYNB, ALGS, and BCTX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Briacell Therap NASDAQ:BCTX

Co-Diagnostics NASDAQ:CODX

Kyntra Bio NASDAQ:KYNB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CODX, KYNB, ALGS, and BCTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CODX, KYNB, ALGS, and BCTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CODX, KYNB, ALGS, and BCTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX, KYNB, ALGS, and BCTX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Briacell Therap NASDAQ:BCTX

Co-Diagnostics NASDAQ:CODX

Kyntra Bio NASDAQ:KYNB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools